Virtual Library
Start Your Search
Sitthi Sukauichai
Author of
-
+
EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.16-35 - Survival of Patients with Small Cell Lung Cancer at a Cancer Hospital in Thailand, 2007-2016 (Now Available) (ID 135)
08:00 - 18:00 | Presenting Author(s): Sitthi Sukauichai
- Abstract
Background
To determine survival of small cell lung cancer (SCLC) patients treated at Chonburi Cancer Hospital (CCH), Thailand.
Method
The researcher conducted this retrospective study by review medical records of SCLC patients treated at CCH from Jan, 2007-Dec, 2016 and follow up until Dec, 2018.
Result
This study enrolled 35 patients with median follow up time 7.9 months. The median age of patients was 61.0. Patient characteristics were male (82.9%), history of smoking (91.4%), clinical SVC obstruction at initial treatment (28.6%), ECOG 0-1 (57.1%), ECOG 2-4 and no record ECOG (42.9%).
Treatment
Concurrent chemo
+definitive TRT
Sequential chemo
+definitive TRT
Sequential chemo
+palliative TRT
Palliative chemo. BSC
+/-
TRT
Total
N=35Stage Limited 4 4 3 0 1 12 Extensive 1 3 3 11 5 23 BSC; best supportive care, Chemo; chemotherapy, TRT; thoracic radiotherapy Treatment modality was shown in the table. The first two most common chemotherapy as first-line regimen was cisplatin/etoposide (n=18) and carboplatin/etoposide (n=10). Treatment response was CR 10.3%, PR 44.9%, SD 10.3%, PD 3.4 % and NA 31%. Prophylaxis cranial irradiation (PCI) was done in one patient.
Overall survival (OS) of the patient received systemic chemotherapy and/or radiotherapy with limited and extensive stage was 17.77 (95%CI;15.22-20.32)(n=11) and 5.94 (95%CI; 2.60-9.23) (n=18) months, respectively, and those of patient received supportive care was 3.28 (95%CI;1.43-5.13)(n=6) months.
Conclusion
The OS of the limited stage SCLC patients at our hospital was comparable to landmark studies. Nevertheless, the small number of the patient received PCI and most received treatment as sequential chemo-radiation.